Brief: Alteogen's Gastric Cancer Drug Gets FDA Approval For Orphan Drug Designation
06/08/2018 14:18
Aug 6 (Reuters) - Alteogen Inc 196170.KQ :
* ALTEOGEN GETS FDA APPROVAL FOR ORPHAN DRUG DESIGNATION
WITH AN
ANTIBODY-DRUG CONJUGATE FOR GASTRIC CANCER
Source text for Eikon: urn:newsml:reuters.com:*:nBw7BSd92a
Further company coverage: 196170.KQ
Recent news on Alteogen
See all newsDeals of the day-Mergers and acquisitions
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
Brief: Alteogen To Invest 253 Billion Won In Construction Of New Factory
Brief: Alteogen Q2 Operating. Profit 34.2 Billion Won
Brief: Alteogen - Signs Exclusive License Agreement For Alt-B4 Recombinant Human Hyaluronidase